Neovasculgen cambiogenplasmid regulatory update

Russia's Human Stem Cells Institute said Russia approved Neovasculgen cambiogenplasmid to treat peripheral arterial disease (PAD). The company plans to launch the plasmid vector containing the VEGF ge...